Latvia
Cellbox Labs represents a promising venture in the rapidly developing field of biotechnology with its focus on Industrial organ on chip technology. Founded in 2020 and headquartered in Latvia, this innovative company is engineering miniature organ replicas externally from the human body. The prime focus is on developing the microbiome and gut on a chip to enhance drug effectiveness and facilitate the study of biological processes.
Additionally, Cellbox Labs is working on a user-friendly instrument to conduct experiments on these chips. Their progress has garnered attention, culminating in a recent €3.30M Early VC investment on 1 August 2025 from notable investor Tech4Care. This funding underscores the potential market impact and the strategic significance of their technological advancement. Investors should consider the promising prospects that this niche area in biotechnology offers, potentially allowing for breakthroughs in drug development and biomedical research.
